Insider · CIK 0001763581
Mark Schoenberg
Files at URGN (UroGen Pharma Ltd.). First filing Jun 11, 2025, latest Sep 9, 2026.
Mark Schoenberg files SEC Form 4 as officer at URGN (UroGen Pharma Ltd.). Since Jun 11, 2025, Mark Schoenberg has reported 0 open-market buys worth $0 and 7 open-market sells worth $763k, the latest filed on Sep 9, 2026.
A track record needs three past buys with six months of prices behind them; Mark Schoenberg has 0, so none is measured yet.
The newest scored trade: sold $37k of URGN on Sep 8, 2026, filed Sep 9, 2026, scored 14 (weak). In the last 12 months: 0 buys worth $0 and 3 sells worth $433k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
URGN: UroGen Pharma Ltd.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 14Weak | UroGen Pharma Ltd. | $37k 871 shares | -1% | - | |
| 34Weak | UroGen Pharma Ltd. | $145k 7,373 shares | -5% | +409% from low-32% from high | |
| 8Weak | UroGen Pharma Ltd. | $250k 10,000 shares | -7% | +543% from low0% from high | |
| 8Weak | UroGen Pharma Ltd. | $17k 871 shares | -1% | +445% from low0% from high | |
| 35Weak | UroGen Pharma Ltd. | $177k 10,000 shares | -6% | +364% from low-12% from high | |
| 18Weak | UroGen Pharma Ltd. | $99k 5,149 shares | -3% | +381% from low-0% from high | |
| 6Weak | URGNsell UroGen Pharma Ltd. | $38k 5,162 shares | -3% | +79% from low-49% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 9, 2025 | URGN UroGen Pharma Ltd. | 871 0.00% of outstanding | $16k | Sep 8, 2025 | $137k |
| Jul 29, 2025 | URGN UroGen Pharma Ltd. | 5,149 0.01% of outstanding | $98k | Jul 28, 2025 | $38k |
| Jun 10, 2025 | URGN UroGen Pharma Ltd. | 5,162 0.01% of outstanding | $38k | Jun 9, 2025 | none |
Transactions
Every row this insider has filed, 23 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 7, 2026 | URGN UroGen Pharma Ltd. | MOption exercise Ordinary Shares | +1,667 | - | - | 60,753 | 34 d ago |
| Sep 8, 2026 | URGN UroGen Pharma Ltd. | SOpen-market sale Ordinary Shares | -871 | $42.92 | $37k | 59,882 | 34 d ago |
| Sep 7, 2026 | URGN UroGen Pharma Ltd. | MOption exercise Restricted Stock Unitsderivative | -1,667 | $0.00 | $0 | 0 | 34 d ago |
| Feb 3, 2026 | URGN UroGen Pharma Ltd. | SOpen-market sale Ordinary Shares | -1,844 | $19.69 | $36k | 150,514 | Feb 4, 2026 |
| Feb 3, 2026 | URGN UroGen Pharma Ltd. | SOpen-market sale Ordinary Shares | -1,843 | $19.69 | $36k | 148,671 | Feb 4, 2026 |
| Feb 3, 2026 | URGN UroGen Pharma Ltd. | SOpen-market sale Ordinary Shares | -3,686 | $19.69 | $73k | 144,985 | Feb 4, 2026 |
| Jan 31, 2026 | URGN UroGen Pharma Ltd. | MOption exercise Ordinary Shares | +3,333 | - | - | 145,692 | Feb 3, 2026 |
| Jan 31, 2026 | URGN UroGen Pharma Ltd. | MOption exercise Ordinary Shares | +6,666 | - | - | 152,358 | Feb 3, 2026 |
| Jan 31, 2026 | URGN UroGen Pharma Ltd. | MOption exercise Ordinary Shares | +3,334 | - | - | 142,359 | Feb 3, 2026 |
| Jan 31, 2026 | URGN UroGen Pharma Ltd. | MOption exercise Restricted Stock Unitsderivative | -3,333 | $0.00 | $0 | 3,334 | Feb 3, 2026 |
| Jan 31, 2026 | URGN UroGen Pharma Ltd. | MOption exercise Restricted Stock Unitsderivative | -6,666 | $0.00 | $0 | 13,334 | Feb 3, 2026 |
| Jan 31, 2026 | URGN UroGen Pharma Ltd. | MOption exercise Restricted Stock Unitsderivative | -3,334 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 31, 2026 | URGN UroGen Pharma Ltd. | AGrant or award Restricted Stock Unitsderivative | +20,000 | $0.00 | $0 | 20,000 | Feb 3, 2026 |
| Nov 19, 2025 | URGN UroGen Pharma Ltd. | SOpen-market sale Ordinary Shares10b5-1 | -10,000 | $25.00 | $250k | 139,025 | Nov 20, 2025 |
| Sep 7, 2025 | URGN UroGen Pharma Ltd. | MOption exercise Ordinary Shares | +1,667 | - | - | 149,896 | Sep 9, 2025 |
| Sep 8, 2025 | URGN UroGen Pharma Ltd. | SOpen-market sale Ordinary Shares | -871 | $19.11 | $17k | 149,025 | Sep 9, 2025 |
| Sep 7, 2025 | URGN UroGen Pharma Ltd. | MOption exercise Restricted Stock Unitsderivative | -1,667 | $0.00 | $0 | 1,667 | Sep 9, 2025 |
| Aug 11, 2025 | URGN UroGen Pharma Ltd. | SOpen-market sale Ordinary Shares | -10,000 | $17.69 | $177k | 148,229 | Aug 13, 2025 |
| Jul 28, 2025 | URGN UroGen Pharma Ltd. | MOption exercise Ordinary Shares | +10,000 | - | - | 163,378 | Jul 30, 2025 |
| Jul 28, 2025 | URGN UroGen Pharma Ltd. | SOpen-market sale Ordinary Shares | -5,149 | $19.14 | $99k | 158,229 | Jul 30, 2025 |
| Jun 8, 2025 | URGN UroGen Pharma Ltd. | MOption exercise Ordinary Shares | +10,000 | - | - | 158,540 | Jun 11, 2025 |
| Jun 9, 2025 | URGN UroGen Pharma Ltd. | SOpen-market sale Ordinary Shares | -5,162 | $7.37 | $38k | 153,378 | Jun 11, 2025 |
| Jun 8, 2025 | URGN UroGen Pharma Ltd. | MOption exercise Restricted Stock Unitsderivative | -10,000 | $0.00 | $0 | 10,000 | Jun 11, 2025 |
Questions about Mark Schoenberg
Answered from the filings on this page, as of the latest one.
Is Mark Schoenberg buying or selling?
In the last 12 months Mark Schoenberg reported 0 open-market buys worth $0 and 3 open-market sells worth $433k on SEC Form 4; the latest was sold $37k of URGN on Sep 8, 2026. Grants, option exercises and tax withholding are not counted.
How did Mark Schoenberg's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mark Schoenberg has 0.
Where does Mark Schoenberg file Form 4?
Mark Schoenberg has filed Form 4 at URGN (UroGen Pharma Ltd.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.